首页> 外文期刊>Journal of Cancer >A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+ breast cancers: a 2538-case multicenter study on consecutive surgical specimens
【24h】

A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+ breast cancers: a 2538-case multicenter study on consecutive surgical specimens

机译:基于决策树的荧光预测模型在HER2免疫组织化学-2 +乳腺癌中的原位杂交HER2基因状况:连续外科标本的2538例多中心研究

获取原文
           

摘要

Objective: To investigate the proportion of HER2 gene amplifications and the association between the HER2-IHC-staining pattern and gene status in IHC-2+ breast cancers according to 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Methods: We retrospectively analyzed and re-evaluated the IHC-staining pattern of 2538 IHC-2+ surgical specimens of breast cancer from November 2014 to October 2015 in 12 institutions. All cases used for building a prediction model of HER2 gene amplification according to the IHC-staining pattern and were randomly divided into a training set (n = 1914) or validation set (n = 624). Results: The overall HER2 fluorescence in situ hybridization (FISH) amplification, non-amplification and equivocation rates in HER2 IHC-2+ cases were 17.8%, 76.2% and 6.0%, respectively. In the training set, cases that had ≤ 10% of cells with intense, complete and circumferential membrane staining or had > 85% of cells with complete membrane staining of any staining intensity tended to be HER2 gene amplified (77.0% and 60.5%, respectively). And cases with weak and incomplete membrane staining had the lowest amplification rate of 6.1%. The prediction model was constructed based on IHC-staining pattern in the training set and validated using a validation set. The positive and negative prediction values were 51.6% and 79.2%, respectively, in the validation set. Moreover, the HER2 copy number per cell was much higher in cases with amplification-associated staining patterns (7.84 and 8.75) than in cases with non-amplification-associated staining patterns (2.97 to 4.41, P < 0.05). Conclusions: In HER2 IHC-2+ breast cancers, the staining pattern is associated with the HER2 gene status. This finding is compatible with recommendations of 2013 ASCO/CAP guidelines.
机译:目的:探讨IHC-2 +乳腺癌海2-IHC染色模式与基因状况的比例,根据2013年美国肿瘤学会(ASCO)/美国病理学家学院(CAP)指导方针。方法:从2014年11月到2015年11月,我们回顾性分析并重新评估了2538年IHC-2 +手术标本的IHC染色模式,从2014年11月到2015年10月12所机构。所有用于根据IHC染色模式构建HER2基因扩增预测模型的案例,并随机分为训练集(n = 1914)或验证组(n = 624)。结果:HER2杂交(鱼类)扩增的总体HER2荧光分别为17.8%,76.2%和6.0%。在训练组中,具有≤10%的壳体≤10%的细胞,具有强烈,完整和周向膜染色或具有完全膜染色的85%的细胞,任何染色强度均为Sher2基因分别(分别为77.0%和60.5%) )。薄弱和不完全膜染色的病例具有6.1%的最低放大率。基于训练集中的IHC染色模式构建预测模型,并使用验证集进行验证。在验证组中,正和负预测值分别为51.6%和79.2%。此外,在扩增相关染色模式(7.84和8.75)的情况下,每种细胞的HER2拷贝数远高于非扩增相关染色模式(2.97至4.41,P <0.05)的情况。结论:在HER2 IHC-2 +乳腺癌中,染色模式与HER2基因状况相关。此发现与2013年ASCO / CAP指南的建议兼容。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号